Publications by authors named "L B Enyedi"
Dermoid Cyst of Conjunctival Origin Attached to the Tarsus in a Pediatric Patient.
Ophthalmic Plast Reconstr Surg
December 2024
Dermoid cysts of cutaneous origin are common orbital lesions, whereas dermoid cysts of conjunctival origin are rare. The authors present a case of a dermoid cyst of conjunctival origin that was attached to the tarsus in a pediatric patient. A 2-year-old boy presented to the clinic with an approximately 2 cm in diameter mobile nodule in the upper eyelid on the temporal side that distorted the eyelid architecture with temporal ptosis.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted as a double-masked, randomized phase 3 trial, participants were assigned to receive either SB15 or AFL, with some switching treatments mid-study, allowing for a direct comparison of outcomes.
- * Results showed that both SB15 and AFL had similar impacts on visual acuity and retinal thickness, and both safety and immunogenicity profiles were comparable, indicating that SB15 could be a viable alternative to AFL in nAMD treatment.
Article Synopsis
- Aflibercept biosimilars like SB15 can enhance treatment options for retinal diseases, potentially increasing patient access to effective therapies.
- A phase 3 trial was conducted with 449 participants aged 50 and older with neovascular age-related macular degeneration to compare the efficacy and safety of SB15 and the reference drug, Aflibercept (AFL).
- The results showed that SB15 produced comparable improvements in visual acuity as AFL after 8 weeks, indicating equivalence in efficacy between the two treatments.
Unilateral four muscle surgery for extra-large monocular exotropia.
Arch Soc Esp Oftalmol (Engl Ed)
July 2023
Introduction: Recurrent exotropia is common following surgery for monocular large angle constant sensory exotropia. Surgery is usually limited to operations on the affected eye. Simultaneous oblique weakening surgery may enhance the effect of the horizontal rectus muscles surgery by decreasing the abducting forces.
View Article and Find Full Text PDFBackground: Anti-vascular endothelial growth factor (VEGF) therapy is currently the most effective therapy of exudative age-related macular degeneration (AMD). The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
Methods: Two clinical trial sites recruited their original subjects for a re-evaluation 7 years after the baseline visit of the phase-3 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW 2) trial.